NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant
Updated: Feb 5
NCT05354557: Phase 2 - Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maintenance therapy.
Sponsor
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT05354557
Official Title: Phase II Multicenter Trial of Iberdomide as Maintenance Therapy for Multiple Myeloma Patients With Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation or After Salvage Autologous Hematopoietic Cell Transplantation
First Posted : April 29, 2022
Click here to see details on ClinicalTrials.gov
Drug: Iberdomide
Locations
United States, New Jersey
United States, New York